Imac Holdings (BACK)
OTHER OTC:BACK
Want to see BACK full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Innovative Care Solutions
IMAC's focus on innovative, non-invasive treatments positions it well in the growing market for alternatives to traditional surgery, potentially driving long-term demand.
Negative Factors
Nasdaq Compliance Challenges
Non-compliance with Nasdaq listing rules poses a risk of delisting, which could limit access to capital markets and negatively impact investor confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Care Solutions
IMAC's focus on innovative, non-invasive treatments positions it well in the growing market for alternatives to traditional surgery, potentially driving long-term demand.
Read all positive factors
Imac Holdings (BACK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$174.11K
Dividend YieldN/A
Average Volume (3M)10.22K
Price to Earnings (P/E)―
Beta (1Y)-0.33
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,784,966
10 Day Avg. Volume9,776
30 Day Avg. Volume10,220
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.31
Price to Sales (P/S)27.67
P/FCF Ratio-0.63
Enterprise Value/Market Cap22.73
Enterprise Value/Revenue174.17
Enterprise Value/Gross Profit-9.47
Enterprise Value/Ebitda-0.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imac Holdings Business Overview & Revenue Model
Company Description
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive proce...
How the Company Makes Money
IMAC Holdings generates revenue primarily through the operation of its medical clinics, which provide a range of healthcare services such as physical therapy, chiropractic care, and regenerative medicine treatments. These services cater to patient...
Imac Holdings Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.72K | 72.05K | 5.20M | 16.19M | 14.39M | 12.84M |
| Gross Profit | -417.84K | -233.20K | 3.85M | 14.68M | 12.76M | 11.21M |
| EBITDA | -8.37M | -5.48M | -5.95M | -10.20M | -8.39M | -3.26M |
| Net Income | -9.70M | -9.05M | -9.42M | -18.31M | -10.54M | -5.57M |
Balance Sheet | ||||||
| Total Assets | 310.06K | 1.59M | 1.14M | 11.08M | 27.23M | 19.75M |
| Cash, Cash Equivalents and Short-Term Investments | 45.05K | 504.19K | 221.51K | 763.21K | 7.12M | 2.62M |
| Total Debt | 3.83M | 0.00 | 0.00 | 4.16M | 5.90M | 9.14M |
| Total Liabilities | 13.29M | 7.98M | 1.90M | 6.43M | 9.28M | 11.93M |
| Stockholders Equity | -12.98M | -6.39M | -752.65K | 4.65M | 17.95M | 10.43M |
Cash Flow | ||||||
| Free Cash Flow | -4.89M | -3.16M | -2.79M | -10.63M | -8.29M | -6.12M |
| Operating Cash Flow | -4.89M | -3.16M | -2.79M | -10.29M | -7.59M | -5.99M |
| Investing Cash Flow | 0.00 | -375.00K | -1.78M | -259.98K | -2.46M | -569.74K |
| Financing Cash Flow | 4.75M | 3.82M | 4.02M | 4.20M | 14.54M | 8.81M |
Imac Holdings Technical Analysis
Neutral
0.06
Price Trends
0.05
Negative
0.07
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
51.92
Neutral
109.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BACK, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.92 is Neutral, neither overbought nor oversold. The STOCH value of 109.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BACK.
Imac Holdings Risk Analysis
Imac Holdings disclosed 45 risk factors in its most recent earnings report. Imac Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Imac Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $174.11K | -0.02 | 105.36% | ― | ― | ― | |
64 Neutral | $125.73M | 24.15 | 16.94% | ― | -35.82% | ― | |
59 Neutral | $100.31M | 2.07 | 184.97% | ― | -0.87% | 10.51% | |
50 Neutral | $8.94M | -3.98 | -8.75% | ― | -0.62% | -200.79% | |
46 Neutral | $27.71M | 145.34 | 15.82% | 11.14% | -2.56% | -2181.76% | |
46 Neutral | $3.72M | -0.56 | -99.99% | ― | -35.26% | 51.06% |
* Healthcare Sector Average
BACK
Imac Holdings
0.05
0.01
39.39%
AMS
American Shared Hospital Services
1.35
-1.02
-43.04%
JYNT
Joint
8.95
-1.15
-11.39%
CCEL
Cryo-Cell International
3.46
-1.37
-28.36%
PIII
P3 Health Partners
13.20
5.94
81.82%
MNDR
Mobile-health Network Solutions Class A
0.86
-5.89
-87.27%
Imac Holdings Corporate Events
Private Placements and Financing
IMAC Holdings Secures Promissory Note for Financial Stability
Neutral
Dec 16, 2025
On December 11, 2025, IMAC Holdings, Inc. issued a secured promissory note to a lender for $247,800 with a purchase price of $177,000, maturing on February 13, 2026. This financial move allows the company to prepay the principal without penalty an...
Private Placements and Financing
IMAC Holdings Issues Secured Promissory Note
Neutral
Dec 1, 2025
On November 25, 2025, IMAC Holdings, Inc. issued a secured promissory note to a lender for $245,000, with a purchase price of $175,000. The note, which matures on February 13, 2026, allows for prepayment without penalty and includes standard coven...
Private Placements and Financing
IMAC Holdings Issues Secured Promissory Note
Neutral
Nov 20, 2025
On November 14, 2025, IMAC Holdings, Inc. issued a secured promissory note to a lender for $210,000, with a purchase price of $150,000, maturing on February 13, 2026. The note allows prepayment without penalty and includes standard legal protectio...
Private Placements and Financing
IMAC Holdings Issues Promissory Note for Liquidity
Neutral
Oct 31, 2025
On October 28, 2025, IMAC Holdings, Inc. issued an unsecured promissory note to a lender for $285,600, with a purchase price of $204,000, maturing on December 24, 2025. This financial maneuver allows the company flexibility in prepayment and inclu...
Private Placements and Financing
IMAC Holdings Issues Unsecured Promissory Note
Neutral
Oct 20, 2025
On October 14, 2025, IMAC Holdings, Inc. issued an unsecured promissory note to a lender for $201,600, with a purchase price of $144,000, maturing on December 24, 2025. The note allows for prepayment without penalty and includes standard clauses f...
Private Placements and Financing
IMAC Holdings Issues Unsecured Promissory Note
Negative
Oct 3, 2025
On September 26, 2025, IMAC Holdings, Inc. issued an unsecured promissory note to a lender for $296,800, with a purchase price of $212,000. The note, which matures on December 24, 2025, allows for prepayment without penalty and includes standard c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―